Actionable news
0
All posts from Actionable news
Actionable news in NVCR: NovoCure Ltd,

Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.

Company broadens geographic reach of Optune in community setting, making therapy more accessible to patients

Internationally, GBM patients can access Optune at an additional 350 medical institutions

ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure™ (NASDAQ: NVCR) announced today that physicians at more than 600 cancer treatment centers in the U.S. have been certified to prescribe Optune to newly diagnosed and recurrent glioblastoma (GBM) patients. Optune is Novocure’s wearable, portable, FDA-approved Tumor Treating Fields (TTFields) delivery system for the treatment of GBM. Physicians at an additional 350 medical institutions throughout the world also can prescribe Optune to GBM patients.

Novocure’s Optune now available at more than 600 cancer treatment centers in the U.S.

Tweet this

“We are proud to have certified physicians at a variety of cancer treatment centers, both large and small, in the community and academic settings, nationally and worldwide,” said Novocure’s CEO Asaf Danzinger. “It is our goal to bring our therapy to all GBM patients who can benefit from it. Optune is now more accessible to GBM patients than ever before, and we remain focused on broadening its reach.”

The latest physician certifications broaden the geographic reach of Optune in the community setting, making the therapy more accessible to patients.

“As a pioneer of community-based oncology, we strive to enhance patient access to innovative cancer treatments so patients can stay connected to the support of their families, friends and community during the challenging time of a cancer diagnosis,” said Dr. Joseph C. Hodges, a radiation oncologist and certified Optune prescriber at Texas Oncology in Longview, Texas. “Optune provides immense benefit to GBM patients, and we are excited to now offer this treatment to our patients.”

About Novocure

Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.

Approved Indications

In the United...


More